Using Targeted Therapies for T Cell Lymphoma Transplant Patients

Jasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses how her institution is working on improving the outcome of patients with T cell lymphoma that undergo transplants.

Clinical Pearls:

• Columbia’s new transplant program is working on moving targeted therapies into the transplant setting
• Columbia’s transplant program is hoping to develop protocols for transplantation that will include targeted therapies such as pralatrexate, romidepsin, and ibrutinib as maintenance therapy to reduce toxicity
• This will ultimately improve the outcome for these patients